Category: Uncategorized

  • Research

    Conceptual Perspective

    Conceptually, ALTERBIOTIC integrates research perspectives from distinct fields, including critical innovation studies, science and technology studies, political economy of pharmaceuticals, and social studies of microbes. Combined, these diverse approaches provide theoretical and analytical sensibilities to guide the research process and to make sense of different aspects and dimensions of alter-biotic innovation processes.  

    On this basis, the project coins and develops the concept ‘alter-biotic innovation’ to investigate the politics of antimicrobial innovation initiatives, and the kinds of social, technical and political alternatives to incumbent regimes of antibiotic development they envision and build. The ‘alter’ in alter-biotic comprises at least the following dimensions: 

    • to bring into view, map and jointly conceptualize the highly diverse set of articulations, visions and practices which have in common that they, in one way or another, problematize and aim to overcome the limitations of antibiotic drug discovery, development and deployment regimes  
    • to facilitate an empirical analysis of the diverse, and often contending, visions and practices that different actors pursue as alternatives to existing antibiotic regimes 
    • to compare and contrast the many competing ‘alter-biotic’ approaches and to examine the key differences between them and how they diverge from incumbent/traditional antibiotic regimes 
    • to theorize the deeply political dimensions of alter-biotic innovation, by investigating the technopolitical and biopolitical implications of AMR crisis and the kinds of alternative futures co-developed with alter-biotic innovation practices 

    Under this conceptual umbrella, ALTERBIOTIC investigates the practical tensions and challenges of current innovation initiatives and re-connects these practical issues with conceptual problems of social and political theory!

    Methodology

    ALTERBIOTIC is an empirically driven, qualitative social science research project that employs a comparative case study approach informed by interpretive methodologies and ethnographic sensibility. This enables the project to engage closely with actors, capture their situated experiences, and analyze the complexities of the field in which they operate, its diverse practices, as well as the tacit assumptions, values and future visions that animate it. 

    ALTERBIOTIC gathers data in a fieldwork-driven research process that deploys several methods including conference and event ethnography, qualitative expert interviews and practice-based document analysis. This engagement enables a deep, comprehensive understanding of alter-biotic innovation and its main actors, (competing) objects, discourses, and institutional arrangements.  

    Research Ethics

    ALTERBIOTIC research is conducted in full compliance with national and European legislation, in particular the GDPR and the European Code of Conduct for Research Integrity (ALLEA).  

    The project engages closely with diverse actors in the antimicrobial innovation field — including scientists, industry representatives, policymakers, and NGOs. Building trustful relations with actors in the field through interaction and dialogue at various sites and occasions is essential for understanding this complex landscape and generating meaningful research outputs. ALTERBIOTIC understands ethnographic sensibility as a commitment to critically reflect the positionality of the team in the field to anticipate, evaluate and mitigate potential bias due to epistemic selectivity and power relations that may occur at various stages in the research. 

  • About

    ALTERBIOTIC investigates the multifaceted global crisis of antimicrobial resistance (AMR) by focusing on the innovation challenges involved in developing new, effective treatments against bacterial infections, and multi-drug-resistant ‘superbugs’ particularly.  

    Antibiotic drugs – encapsulating the triumph of modern medicine over bacteria – are indispensable for healthcare and public health. Yet, their decades-long excessive global use has rapidly undermined their efficacy, as bacteria are becoming resistant to the very antibiotics that once easily eradicated them. In a recent report, the World Health Organization has found that already 1 in 6 infections occurring worldwide shows resistance to those antibiotics commonly used to treat the infection (World Health Organization 2025). Already today, the global health burden imposed by AMR is considerable. AMR was directly responsible for an estimated 1.2 million deaths globally in 2019, with additionally nearly 5 million deaths associated with resistant infections—exceeding the death toll of major infectious diseases like HIV/AIDS and malaria (Murray et al. 2022). Beyond this health burden, AMR is also projected to impose a staggering economic burden, with global losses potentially reaching up to 100 trillion USD by 2050 (Countryman and McDonnell 2025) due to a combination of escalating healthcare expenditures, prolonged illness, increased mortality, and a significant decline in livestock production. 

    AMR has been formally recognized by leading global institutions—including the United Nations (UN), the World Health Organization (WHO), and the G7 and G20 summits—as a critical threat to global health security and sustainable development that demands urgent, coordinated, and multi-sectoral action. 

    Whilst the main drivers of AMR are decade-long overuse and misuse of antibiotics globally, it is exacerbated by a significant decline in antibiotic R&D and resulting innovation crisis. Despite the urgent need for new, effective antibiotics, the big industry players that have traditionally supplied society with new antibiotics have largely abandoned this field over the past decades due to scientific and commercial challenges.  

    This predicament presents society with the challenge of revising the policy frameworks and innovation models that guide how essential medicines are developed, valued, and deployed across society. ALTERBIOTIC investigates current efforts to rebuild the antimicrobial innovation ecosystem by examining how key actors from science, industry, and policy imagine and pursue robust solutions to the AMR health and innovation crisis. Empirically, the project maps emerging alternative clinical, regulatory, and economic approaches to drive biomedical R&D in this field and analyses the complex political and technical ‘innovation challenges’ related to the timely, sustainable, and equitable development of new, effective antibacterial therapies. 

    ALTERBIOTIC conceptualizes AMR as a deep-seated crisis that puts into question dominant regimes of health, growth, and security, which have long depended on readily available and effective pharmaceuticals. 

     

    References

    Countryman, Amanda, and Anthony McDonnell. 2025. “Modelling the Global Economic Impact of Antimicrobial Resistance in Humans.” https://www.cgdev.org/publication/modelling-global-economic-impact-antimicrobial-resistance-humans. 

    Murray, Christopher J. L. et al. 2022. “Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis.” The Lancet 399(10325):629–55. doi:10.1016/S0140-6736(21)02724-0. 

    World Health Organization. 2025. Global Antibiotic Resistance Surveillance Report 2025: WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS). Geneva.